

**Zeitschrift:** Acta Tropica  
**Herausgeber:** Schweizerisches Tropeninstitut (Basel)  
**Band:** 43 (1986)  
**Heft:** 4

**Artikel:** Use of procyclic trypanosomes for detection of antibodies in sera from vervet monkeys infected with "Trypanosoma rhodesiense" : an immunodiagnostic test for African sleeping sickness  
**Autor:** Pearson, T.W. / Liu, M. / Gardiner, I.C.  
**DOI:** <https://doi.org/10.5169/seals-313650>

### **Nutzungsbedingungen**

Die ETH-Bibliothek ist die Anbieterin der digitalisierten Zeitschriften. Sie besitzt keine Urheberrechte an den Zeitschriften und ist nicht verantwortlich für deren Inhalte. Die Rechte liegen in der Regel bei den Herausgebern beziehungsweise den externen Rechteinhabern. [Siehe Rechtliche Hinweise.](#)

### **Conditions d'utilisation**

L'ETH Library est le fournisseur des revues numérisées. Elle ne détient aucun droit d'auteur sur les revues et n'est pas responsable de leur contenu. En règle générale, les droits sont détenus par les éditeurs ou les détenteurs de droits externes. [Voir Informations légales.](#)

### **Terms of use**

The ETH Library is the provider of the digitised journals. It does not own any copyrights to the journals and is not responsible for their content. The rights usually lie with the publishers or the external rights holders. [See Legal notice.](#)

**Download PDF:** 14.05.2025

**ETH-Bibliothek Zürich, E-Periodica, <https://www.e-periodica.ch>**

<sup>1</sup> Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada

<sup>2</sup> Kenya Trypanosomiasis Research Institute, Muguga, Kenya

## **Use of procyclic trypanosomes for detection of antibodies in sera from vervet monkeys infected with *Trypanosoma rhodesiense*: an immunodiagnostic test for African sleeping sickness**

T. W. PEARSON<sup>1</sup>, M. LIU<sup>1</sup>, I. C. GARDINER<sup>1</sup>, D. LONGRIDGE<sup>1</sup>, R. P. BEECROFT<sup>1</sup>, P. D. SAYER<sup>2</sup>, S. S. GOULD<sup>2</sup>, J. N. WAITUMBI<sup>2</sup>, A. R. NJOGU<sup>2</sup>

### **Summary**

Uncoated procyclic culture forms of African trypanosomes were used in immunofluorescence and simple agglutination assays to detect antibodies in the sera of vervet monkeys infected with *T. b. rhodesiense*. Antibodies to procyclic surface antigens were found in sera from animals with active, untreated infections or sera taken soon after treatment with trypanocidal drugs. The antibodies were detectable within 7 days of infection. No specific antibodies were detected in sera prior to infection or long after drug cure. The results indicate that antigens expressed on the surface of procyclic culture forms of *T. brucei* spp. are useful for the detection of antibodies produced in response to infection with *T. b. rhodesiense* and may allow the development of a simple immunodiagnostic test for African sleeping sickness. In addition, the use of a form of the trypanosome of a different differentiation state from the infecting organism illustrates the utility of this approach for detection of antibodies to common antigens.

**Key words:** protozoan parasites; procyclic culture forms; immunodiagnosis; *Trypanosoma brucei rhodesiense*.

### **Introduction**

Diagnosis of African sleeping sickness in humans is usually performed by parasitological techniques involving microscopical detection of parasites (WHO, 1979). Such methods are often not definitive as the number of parasites may not be sufficiently high for detection. Detection of specific antibodies in

---

Correspondence: Dr. T. W. Pearson, Department of Biochemistry and Microbiology, University of Victoria, Victoria, B. C. Canada, V8W 2Y2

human sera, although not necessarily indicative of active infection, has proven to be extremely useful for diagnosis of sleeping sickness caused by *T. b. gambiense* (WHO, 1981). The test most successfully used for antibody detection in this form of sleeping sickness is the Card Agglutination Trypanosomiasis Test (C.A.T.T.) which depends on agglutination of fixed, stained, bloodstream *T. b. gambiense* bearing a particular variant surface glycoprotein (VSG) (Magnus et al., 1978). Most humans parasitized with *T. b. gambiense* produce antibodies to this VSG, indicating that trypanosomes of this variable antigenic type appear often in an infected human population. The C.A.T.T. test cannot be used for diagnosis of infections caused by *T. b. rhodesiense* since antibodies to the particular VSG used are not produced in these infections, nor has a similarly frequently occurring variable antigenic type been found with *T. b. rhodesiense* (WHO, 1981).

In this paper we report the use of procyclic culture forms of *T. brucei* spp. for detection of antibodies produced in response to infections with *T. b. rhodesiense*. We used vervet monkeys and *T. b. rhodesiense* EATRO 1989, a model which, with respect to the course of the disease and to parasitological, haematological, immunological and histological parameters, closely resembles human infections with *T. b. rhodesiense* (Schmidt and Sayer, 1982a). Since it is known that procyclic culture forms and bloodstream forms of African trypanosomes share some common antigens (reviewed by Shapiro and Pearson, 1986), we used procyclic culture forms (which are devoid of surface VSG) to detect antibodies made to such antigens during infection.

## Materials and Methods

*Parasites.* The organisms used for infection were *T. b. rhodesiense* KETRI 2537 or KETRI 2545, derived from EATRO 1989 (Fink and Schmidt, 1979), which in vervet monkeys causes chronic disease (Schmidt and Sayer, 1982b) and late phase encephalitis (Schmidt and Sayer, 1982b), both characteristic of human sleeping sickness caused by *T. b. rhodesiense*. Procyclic culture forms were established from cloned bloodstream populations of *T. b. rhodesiense* ViTat 1.1 (Richardson et al., 1986) using the methods of Brun and Schönenberger (1979) and were maintained in SDM-79 medium as described by the latter authors. Promastigotes of a clone of *L. major* NIH (Seidman strain) were grown in the same medium.

*Monkeys, infections and treatment.* Vervet monkeys (*Cercopithecus aethiops*) were used throughout. These monkeys were maintained at KETRI for studies under the UNDP/World Bank/WHO Special Programme on the Chemotherapy of human African trypanosomiasis.

Prior to infection, all monkeys had undergone quarantine of not less than three months duration. During this time the monkeys became adapted to cage life and the presence of humans. They were examined clinically and repeated checks made for evidence of disease, including tuberculosis, intestinal protozoa and helminths and various viral diseases, including Marburg disease, Rift Valley Fever, Ebola and Congo haemorrhagic fever.

The monkeys were infected by intravenous injection of  $10^3$  *T. b. rhodesiense* suspended in phosphate buffered saline containing 1% glucose (PSG). Capillary blood samples were taken daily from the ear tip and examined for trypanosomes. Every two weeks (and occasionally, weekly) after infection the monkeys were anaesthetised and examined clinically; blood was collected for serology and haematology; electrocardiography was performed and cerebrospinal fluid collected.

Between days 28–42 of infection, the monkeys were treated with trypanocidal drugs. The drugs used and the time of serum sampling since drug treatment are indicated in the results. A number of monkeys required drug treatment a second or third time following relapse. Other monkeys were not treated until signs of encephalitis became apparent four to six months after infection. Serum and CSP samples were collected at various intervals and stored at  $-20^{\circ}\text{C}$ .

**Quantitation of IgM and IgG.** Levels of IgM and IgG in vervet monkey sera were determined by radial immunodiffusion (Mancini, 1965) using commercially prepared plates for measurement of human IgM and IgG (Diffugen, TAGO, Inc., Burlingame, California). Human IgM and IgG were used as standards, thus the test may not be quantitative for monkey immunoglobulins. Nevertheless, relative immunoglobulin levels were accurately determined. Some sera were diluted 1/5 in saline in order to obtain accurate readings.

**Immunofluorescence.** Antibodies specific for the surface of *T. b. rhodesiense* ViTat 1.1 procyclic culture forms were measured by indirect immunofluorescence. Procyclic trypanosomes or *Leishmania* promastigotes were centrifuged ( $1000 \times g$ , 15 min,  $4^{\circ}\text{C}$ ) from culture medium, washed once ( $1000 \times g$ , 15 min,  $4^{\circ}\text{C}$ ) with PSG and 10% heat-inactivated foetal bovine serum (FBS) and adjusted to  $1 \times 10^8$  cells/ml in PSG/10% FCS. To  $15 \times 75$  mm glass test tubes were added  $20 \mu\text{l}$  of parasite suspension and  $50 \mu\text{l}$  of human or vervet sera diluted in PSG/10% FBS. The tubes were incubated on ice for 1 h, washed three times with 2.0 ml of PSG/10% FBS and  $20 \mu\text{l}$  of fluoresceinated, affinity-purified goat anti-human IgM or IgG (TAGO, Inc., Burlingame, California) were added. After 1 h incubation on ice, the parasites were washed 3 times as above, resuspended in  $50 \mu\text{l}$  of PSG/10% FBS and  $10 \mu\text{l}$  amounts used to prepare slides for microscopy. Immunofluorescence was observed using a Zeiss Standard binocular microscope fitted with an epi-fluorescence attachment and a Zeiss Neofluor 63/1.25 oil immersion objective.

**Agglutination test.** Antibodies to surface antigens of procyclic culture forms of trypanosomes or promastigote culture forms of *Leishmania* parasites were measured in simple agglutination assays. The organisms were grown to log-phase, washed twice with PSG/10% FBS by centrifugation at  $1000 \times g$ , 10 min at room temperature and adjusted to  $5 \times 10^7$ /ml in PSG/10% FBS. Within 5 min,  $25 \mu\text{l}$  amounts of the suspension were added to flat-bottom microtitration plate wells (Titertek, 96 well, Flow laboratories) containing  $25 \mu\text{l}$  of sera dilutions (1/10–1/320 in doubling dilutions). Control wells contained PSG/10% FBS or sera from mice infected with *T. b. rhodesiense* ViTat 1.1 bloodstream forms, sera from humans with *T. b. gambiense* infections and sera from uninfected north Americans. The plates were shaken for 10 sec to mix their contents and incubated for 5 min at  $26^{\circ}\text{C}$ . Agglutination was observed using an inverted microscope at  $200\times$  magnification and scored as 4+ (total agglutination – all organisms in one or two large aggregates) to 1+ (some agglutination – organisms in one or two large aggregates) to 1- (some agglutination – organisms in small aggregates of 3–5 organisms). Since, within about 20 min, small amounts of aggregates were often seen in the PSG/10% FBS controls, it was important to perform the test quickly and to refer periodically to the negative controls.

## Results

Sera from a total of twelve vervet monkeys were prepared prior to infection, during infection with *T. b. rhodesiense* or after treatment of the infected monkeys with trypanocidal drugs. Sera were numbered according to the number of the monkey and the number of bleeds, e.g. serum 128–1 is from monkey no. 128, bleed no. 1. For ease of discussion, sera (including controls), were also numbered consecutively, from 1 to 49. Total IgM and IgG levels and specific Ig titres in immunofluorescence and agglutination assays using living procyclic trypanosomes were determined for each serum sample. The results are shown in Table 1.

Agglutination of procyclic culture forms of *T. b. rhodesiense* ViTat 1.1 correlated with the status of infection. Thus, no agglutination was observed with

Table 1. Measurement<sup>a</sup> of anti-procyclic surface antibodies in vervet monkey sera before and during infection with *T. b. rhodesiense* and at various times after treatment with trypanocidal drugs

| Serum No. | Monkey No. | No. of days since infection <sup>b</sup> | No. of days since treatment <sup>c</sup> | Remarks  | Ig levels (mg/ml) |      | Immunofluorescence titre vs. <i>T. b. rhodesiense</i> |      | Agglutination titre vs. <i>T. b. rhodesiense</i> |
|-----------|------------|--|--|--|-------------------|------|---|------|--|
|           |            |  |  |  | IgM               | IgG  | IgM   | IgG  |  |
| 1         | 34         | 940                                      | 859 (Mcl. B.)                            |  | 12.0              | 51.5 | —   | —    | —  |
| 2         | 35         | 978                                      | 933 (Suramin/M. K. 436)                  |  | 3.3               | 16.0 | —   | —    | —  |
| 3         | 47-1       | 0  | 0  | Preinfection   | N.D.              | N.D. | N.D.  | N.D. | —  |
| 4         | 47-2       | 7  | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | —  |
| 5         | 47-3       | 14                                       | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | 1/80   |
| 6         | 47-4       | 28                                       | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | 1/160  |
| 7         | 47-5       | 56                                       | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | > 1/320  |
| 8         | 49-1       | 0  | 0  | Preinfection   | N.D.              | N.D. | N.D.  | N.D. | 1/320  |
| 9         | 49-2       | 7  | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | 1/20   |
| 10        | 49-3       | 14                                       | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | 1/160  |
| 11        | 49-4       | 28                                       | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | 1/80   |
| 12        | 49-5       | 56                                       | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | 1/80   |
| 13        | 61         | 875                                      | 793 (Berenil)                            | 528 days since last pos. (CSP)                       | 1.9               | 8.0  | —   | —    | —  |
| 14        | 85-1       | 392                                      | 130 (Suramin/M. K. 436)                  | 29 days since last pos. (blood, CSP) (2nd treatment) | N.D.              | N.D. | N.D.  | N.D. | —  |
| 15        | 85-2       | 605                                      | 343 (Suramin/M. K. 436)                  | 213 days since last pos. (blood) (2nd treatment)     | 5.6               | 10.7 | —   | —    | —  |
| 16        | 94-1       | 0  | 0  | Preinfection   | N.D.              | N.D. | N.D.  | N.D. | —  |
| 17        | 94-2       | 28                                       | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | > 1/320  |
| 18        | 94-3       | 352                                      | 158 (Suramin/TS. 88)                     | 11 days since last pos. (3rd treatment)              | 77.5              | 30.0 | 1/100   | 1/5  | 1/320  |
| 19        | 96-1       | 0  | 0  | Preinfection   | 2.3               | 15.3 | 1/10  | —    | 1/120  |
| 20        | 96-2       | 14                                       | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | 1/40   |
| 21        | 96-3       | 28                                       | 0  | Pretreatment   | 35.0              | 30.0 | 1/100   | —    | > 1/320  |
| 22        | 96-4       | 58                                       | 14 (Suramin/TS. 88)                      | 1st and only treatment                               | N.D.              | N.D. | N.D.  | N.D. | 1/80   |
| 23        | 96-5       | 71                                       | 27 (Suramin/TS. 88)                      | 1st and only treatment                               | 11.5              | 26.5 | 1/10  | —    | 1/40   |
| 24        | 96-6       | 202                                      | 158 (Suramin/TS. 88)                     | 1st and only treatment                               | 1.6               | 14.5 | 1/10  | —    | —  |
| 25        | 113        | 0  | 0  | Preinfection   | 1.6               | 16.0 | 1/10  | 1/10 | 1/20   |
| 26        | 115-1      | 0  | 0  | Preinfection   | 2.1               | 32.5 | —   | 1/10 | 1/80   |
| 27        | 115-2      | 16                                       | 0  | Pretreatment   | N.D.              | N.D. | N.D.  | N.D. | 1/40   |
| 28        | 115-3      | 33                                       | 0  | Pretreatment   | 21.0              | 31.0 | 1/10  | —    | 1/160  |

Table 1 (continued)

| Serum No. | Monkey No. | No. of days since infection <sup>b</sup> | No. of days since treatment <sup>c</sup><br>(drug in brackets) | Remarks   | Ig levels (mg/ml) |      | Immunofluorescence titre vs. <i>T. b. rhodesiense</i> |       | Agglutination titre vs. <i>T. b. rhodesiense</i> |
|-----------|------------|--|--|---|-------------------|------|---|-------|--|
|           |            |  |  |   | IgM               | IgG  | IgM   | IgG   |  |
| 29        | 115-4      | 56                                       | 12 (TS. 88)  | 1st treatment (relapsed later)                        | N.D.              | N.D. | N.D.  | N.D.  | 1/320  |
| 30        | 115-5      | 70                                       | 26 (TS. 88)  | 1st treatment (relapsed later)                        | N.D.              | N.D. | N.D.  | N.D.  | 1/160  |
| 31        | 115-6      | 98                                       | 54 (TS. 88)  | 1st treatment (relapsed later)                        | 24.0              | 51.5 | 1/10  | 1/10  | 1/320  |
| 32        | 124-1      | 0  | 0  | Preinfection  | 2.6               | 30.0 | 1/10  | 1/10  | —  |
| 33        | 124-2      | 16                                       | 0  | Pretreatment  | N.D.              | N.D. | N.D.  | N.D.  | 1/40   |
| 34        | 124-3      | 33                                       | 0  | Pretreatment  | 19.2              | 23.5 | —   | —     | 1/320  |
| 35        | 124-4      | 352                                      | 105 (TS. 88)   | 3rd treatment (Suramin/TS. 88, 1st + 2nd)             | 4.1               | 32.5 | —   | —     | —  |
| 36        | 128-1      | 0  | 0  | Preinfection  | 4.8               | 36.5 | 1/10  | —     | 1/10   |
| 37        | 128-2      | 16                                       | 0  | Pretreatment  | N.D.              | N.D. | N.D.  | N.D.  | 1/320  |
| 38        | 128-3      | 33                                       | 0  | Pretreatment  | 24.0              | 31.0 | 1/100   | 1/5   | 1/80   |
| 39        | 128-4      | 41                                       | 0  | Pretreatment  | N.D.              | N.D. | N.D.  | N.D.  | 1/80   |
| 40        | 128-5      | 352                                      | 278 (Suramin/TS. 88)   | 132 days since last pos. blood (2nd treatment)        | 26.0              | 21.5 | 1/10  | 1/10  | 1/320  |
| 41        | 128-6      | 366                                      | 292 (Suramin/TS. 88)   | 146 days since last pos. blood                        | N.D.              | N.D. | N.D.  | N.D.  | —  |
| 42        | 96-CSF     | 71                                       | 27 (Suramin/TS. 88)  |   | N.D.              | N.D. | N.D.  | N.D.  | —  |
| 43        | 115-CSF    | 33                                       | 0  |   | N.D.              | N.D. | N.D.  | N.D.  | —  |
| 44        | neg.       | 0  | 0  | Human serum (north American)                          | N.D.              | N.D. | —   | —     | —  |
| 45        | neg.       | 0  | 0  | Human serum (north American)                          | N.D.              | N.D. | —   | —     | —  |
| 46        | pos.       | unknown                                  | 7 (Arsobal)  | Human serum (Ivory Coast)                             | N.D.              | N.D. | 1/100   | 1/100 | 1/320  |
| 47        | pos.       | unknown                                  | 7 (Arsobal)  | Human serum (Ivory Coast)                             | N.D.              | N.D. | 1/100   | 1/100 | 1/320  |
| 48        | neg.       | 0  | 0  | Mouse serum (uninfected)                              | N.D.              | N.D. | —   | —     | —  |
| 49        | pos.       | 21                                       | 0  | Mouse serum (infected with <i>T. b. rhodesiense</i> ) | N.D.              | N.D. | —   | —     | 1/320  |

<sup>a</sup> each serum was tested twice in each assay each time by a different investigator<sup>b</sup> animals were infected with *T. b. rhodesiense* KETRI 2537 except No. 61 which was infected with *T. b. rhodesiense* KETRI 2545<sup>c</sup> drug treatment

ND = Not done



sera taken from monkeys prior to infection (sera nos. 3, 8, 16, 32) or sera taken long after drug treatment (days 105–933; sera nos. 1, 2, 13, 15, 24, 35, 41). In addition, no agglutination was seen with one serum (no. 4) taken 7 days after infection, with one serum taken 14 days after drug treatment (no. 14) or with two CSF samples, one taken during an active infection (33 days) and one taken 27 days after drug treatment of the animal (nos. 43 and 42, respectively).

Low agglutination titres (1/10–1/80) were found with sera from early untreated infections (days 7–56; sera nos. 5, 9, 11, 12, 20, 27, 28, 33, 38, 39) or with sera taken 14 and 27 days after drug treatment of infected monkeys (sera nos. 22 and 23, respectively). Preinfection sera (nos. 19, 25, 26, 36) showed titres of 1/20, 1/20, 1/80 and 1/10, respectively.

High agglutination titres (1/160–1/320) were associated with active untreated infections (sera nos. 6, 7, 10, 17, 21, 28, 34 and 37) and were observed as early as day 14 of infection (serum 10). High titres were also seen in two monkeys after drug treatment (sera nos. 18, 29, 30 and 31). Both of these animals later showed relapse infections. Only in one case (serum no. 40) was there a high agglutination titre long after drug treatment (132 days since parasites were last observed) and this animal became negative 24 days later.

Control sera from uninfected north American humans (sera 44 and 45) or from normal uninfected BALB/c mice (serum 48) did not cause agglutination of procyclic trypanosomes whereas sera from west African humans with *T. b. gambiense* infections (sera nos. 46 and 47), or from BALB/c mice infected for 14 days with *T. b. rhodesiense* ViTat 1.1 bloodstream form trypanosomes (serum no. 49), had agglutination titres of 1/320. All sera from humans (control sera) and from the vervet monkeys (test sera) were tested in agglutination assays with *Leishmania major* culture form promastigotes. No agglutination titres above 1/10 were found (data not shown).

Immunofluorescence reactions showed that specific IgM levels reflected the agglutination titres in some but not all sera. Specific IgG levels measured by immunofluorescence on living *T. b. rhodesiense* procyclics did not correlate with agglutination titres. None of the sera tested showed any reaction with the surface of *L. major* promastigotes when tested by immunofluorescence.

Table 2. Total IgM and IgG levels<sup>a</sup> in vervet monkey sera before and during infection with *T. b. rhodesiense* and after drug treatment

|                        | Sera   | IgM (Mean±S.D.)      | IgG (Mean±S.D.) |
|------------------------|--------|----------------------|-----------------|
| Preinfection . . . . . | n = 5  | 2.7±0.4 <sup>b</sup> | 26.1±9.1        |
| Infected . . . . .     | n = 4  | 24.8±7.1             | 28.9±3.6        |
| Drug treated . . . . . | n = 10 | 16.8±23.1            | 26.3±15.5       |

<sup>a</sup> Determined by radial immunodiffusion

<sup>b</sup> mg/ml

Total IgM and IgG levels were determined by radial immunodiffusion using anti-human Ig immunodiffusion plates and human Ig as standards. The results are summarized in Table 2. IgM levels increased dramatically in infected animals and remained elevated after drug treatment. The total IgM levels thus correlated well with the agglutination titres. Mean IgG levels changed little during infection and after drug treatment although a few animals showed increased IgG levels. There was no obvious group correlation of IgG levels with agglutination titres.

## Discussion

Procyclic forms of African trypanosomes share antigens with bloodstream forms (reviewed by Shapiro and Pearson, 1986). Thus it is not surprising that we detected antibodies to procyclic surface antigens in sera from mice, vervet monkeys and humans infected with bloodstream stages of the parasites. Our data showed that we were able to detect anti-procyclic antibodies in vervet monkey sera as early as 7 days after infection with *T. b. rhodesiense*.

Indeed, all sera from monkeys with active, untreated infections (except one 7 day infection serum – no. 4) gave good agglutination titres as did sera taken soon after treatment of infected monkeys with trypanocidal drugs. Thus 14 and 27 days after drug treatment, animal no. 96 (sera nos. 22 and 23) showed titres of 1/80 and 1/40, respectively. Animal 94 (serum 18) showed a titre of 1/320 158 days after final drug treatment but this animal was treated three times with suramin/TS 88 and the serum was taken only 11 days after parasites were last seen in the blood (147 days after the 3rd drug treatment). Sera from animal 115 (sera nos. 29, 30 and 31) taken 12, 26 and 54 days after drug treatment had high agglutination titres. This animal was treated only once with drug and subsequently relapsed.

In all cases but two (serum 18 – see above, and serum 40), sera taken long after successful drug treatment showed no agglutination. Thus, as early as 14 days after treatment with trypanocidal drugs and certainly by 146 days (serum no. 41 taken 24 days after serum 40) agglutination titres dropped to zero.

The only false positive agglutination reaction was with preinfection serum no. 26 which showed a titre of 1/80. All other preinfection or negative control sera showed titres of 0, 1/10 or 1/20.

It is clear therefore, that simple agglutination of procyclic culture forms of trypanosomes can give useful information regarding the infection status of monkeys infected with *T. b. rhodesiense* organisms. Indeed, positive agglutination reactions were found with 6/6 of animals with active trypanosome infections and in animal 96 (sera 22 and 23) taken early after successful drug cure. Negative agglutination reactions were seen with all sera taken long after drug cure except those discussed above which subsequently showed relapse infections.



That the agglutination reactions and immunofluorescence detected trypanosome-specific antibodies was shown by the negative reactions obtained using *Leishmania major* as antigen. Agglutination of procyclic culture forms of all three *T. brucei* subspecies (*T. b. brucei*, *T. b. rhodesiense*, and *T. b. gambiense*) occurred with all of several sera tested from infected vervet monkeys, humans and mice (data not shown). This indicated that antigens shared between both bloodstream and procyclic stages of the *T. brucei* subspecies may allow detection of antibodies produced in human infections with both *T. b. gambiense* and *T. b. rhodesiense* and in cattle infections with *T. b. brucei*. Diagnosis of *T. b. gambiense* infections in patients from the Ivory Coast has been achieved using the simple procyclic agglutination test described here (Gardiner et al., in preparation) and limited results obtained with patients from Western Kenya indicate that diagnosis of sleeping sickness caused by *T. b. rhodesiense* may also be possible.

The potential utility of procyclic trypanosome surface antigens in a simple immunodiagnostic test for African sleeping sickness will only be known after extensive testing of well documented sera from sleeping sickness patients and from control patients in endemic areas. Such testing is underway. In addition, attempts are being made to identify and biochemically characterize the relevant antigens to aid in the development of a stable, simple test for field use.

#### Acknowledgments

We thank Dr. Peter Gardiner for helpful discussion, Dr. Pierre Cattand for the west African serum samples and Marion Kanyugo for typing the manuscript. This investigation received financial assistance from the International Development Research Centre of Canada and from the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.

- Brun R., Schönenberger M.: Cultivation and in vitro cloning of procyclic culture forms of *Trypanosoma brucei* in a semi-defined medium. *Acta trop. (Basel)* 36, 289–292 (1979).
- Fink E., Schmidt H.: Meningoencephalitis in chronic *Trypanosoma brucei rhodesiense* infection of the white mouse. *Tropenmed. Parasit.* 30, 206–211 (1979).
- Magnus E., Vervoort T., Van Meirvenne N.: A card agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of *T. b. gambiense* trypanosomiasis. *Ann. Soc. belge Méd. trop.* 58, 169–176 (1978).
- Mancini G., Carbonara A. O., Heremans J. F.: Immunochemical quantitation of antigens by single radial immunodiffusion. *Immunochemistry* 2, 235–238 (1965).
- Richardson J. P., Jenni L., Beecroft R. P., Pearson T. W.: Procyclic tsetse fly midgut forms and culture forms of African trypanosomes share stage- and species-specific surface antigens identified by monoclonal antibodies. *J. Immunol.* 136, 2259–2264 (1986).
- Schmidt H., Sayer P.: *Trypanosoma brucei rhodesiense* infection in vervet monkeys. I. Parasitologic, hematologic, immunologic and histologic results. *Tropenmed. Parasit.* 33, 249–254 (1982a).
- Schmidt H., Sayer P.: *Trypanosoma brucei rhodesiense* infection in vervet monkeys. II. Provocation of the encephalitic late phase by treatment of infected monkeys. *Tropenmed. Parasit.* 33, 255–259 (1982b).

- Shapiro S. Z., Pearson T. W.: African trypanosomiasis: antigens and host-parasite interactions. In: Parasite antigens: toward new strategies for vaccines, ed. by T. W. Pearson, p.215–274. Marcel Dekker, Inc., New York/Basel 1986.
- World Health Organization: The African Trypanosomiasis. Technical Report Series 635. WHO, Geneva 1979.
- World Health Organization: Scientific Working Group on African Trypanosomiasis. Antwerp 1981.

